IL1B and psoriasis: Considering that the efficacy of saccharin is comparable to that of IL-1 receptor blockade in reducing the pathological signs of psoriasis, the number of IL-17 A-producing T cells, and inflammatory cytokine levels, we speculate that saccharin is an eligible and alternative candidate for the topical treatment of psoriasis via its anti-inflammatory effect on IL-1β.